Alnylam Pharmaceutical is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Canada. For disease awareness purposes only.
Contact Alnylam ATTR for Cardio

hATTR is rare. Diagnosing and treating it doesn’t have to be.

Suspect hATTR earlier, change a patient’s life. 

Hereditary Amyloidosis (hATTR) is an inherited, rapidly progressive, life-threatening, multisystem disease that often goes undiagnosed or misdiagnosed due to variable clinical presentation and non-specific symptoms.1,2

Early detection is critical. A simple, quick, genetic test is available at no cost, and can help you provide patients with answers - and treatment.

Progressive neuropathy that appears idiopathic could be hATTR, making it crucial to include it in your differential diagnosis.3

Download the HCP Resource

Get a full overview of hATTR to help make accurate clinical decisions. 

Healthcare professional reviewing clinical red flags for hereditary transthyretin amyloidosis (hATTR)
Learn more about hATTR

Treatment is available and can improve patient outcomes.

hATTR identified in practices like your

Red flags to watch for.

Suspecting hATTR can help you diagnose earlier.

hATTR can present in highly variable ways and may seem idiopathic at first. Recognizing key symptom clusters is essential to suspecting an underlying cause.1,6

Progressive symmetric sensory-motor neuropathy

Progressive symmetric sensory-motor neuropathy

Nephropathy presenting with proteinuria and renal failure

Nephropathy (proteinuria, renal failure)

Cardiovascular symptoms including shortness of breath, arrhythmias, and heart failure

Cardiovascular complaints (shortness of breath, arrhythmias, previously diagnosed heart failure)

Gastrointestinal symptoms including nausea, vomiting, diarrhea, constipation, weight loss, and early satiety

GI complaints (nausea and vomiting, diarrhea, severe constipation, weight loss, early satiety)

Autonomic neuropathy including orthostatic hypotension, urinary tract infections, sexual dysfunction, and sweating abnormalities

Autonomic neuropathy (orthostatic hypotension, recurrent UTIs, sexual dysfunction, sweating)

Bilateral carpal tunnel syndrome

Bilateral carpal tunnel syndrome

Family history of symptoms associated with hereditary transthyretin amyloidosis

Family history of any of the above symptoms

Download the Patient Assessment Tool today.

Get the tool now

A neurologist’s tool for understanding and diagnosing hATTR.

Diagnosing hATTR

hATTR is treatable, making early diagnosis and intervention crucial. The sooner you suspect it in your patients, the better you can slow or even
stop its progression.7 Consider the red flags for hATTR when developing your differential diagnosis.1,6 Remember: suspect, diagnose, and test.

Step 1: Suspect

Step 1: Suspect hATTR in patients with progressive symmetric sensory-motor neuropathy and red flags

If a patient is presenting with progressive symmetric sensory-motor neuropathy and at
least one of the red flags listed, include hATTR in your differential diagnosis. Similarly, if a patient presenting with neuropathic symptoms is unresponsive to treatment for their current diagnosis—or suspected diagnosis—hATTR should be considered.1,3,8

Step 2: Diagnose

Step 2: Diagnose hATTR using peripheral nerve testing

To diagnose hATTR, perform peripheral nerve
testing (PN testing). Assess sensory and motor
skills, as reduced responses in hands and feet can indicate polyneuropathy consistent
with hATTR.1,6

Step 3: Test

Step 3: Confirm hATTR diagnosis with genetic testing or referral to a Canadian amyloidosis expert

Confirm a hATTR diagnosis with genetic testing at no charge to patients and HCP available through Alnylam Act.
 

You may also refer the patient to 
a Canadian Amyloidosis Expert for 
further testing or support.

Resources are available for your practice. Contact us.

Contact an Alnylam representative to learn more about hATTR, diagnostic resources, and treatment options.

By submitting this form, I declare that:

I expressly agree to the processing of my personal data by Alnylam, for the purposes of future communications and interactions with Alnylam, by electronic means, for the provision of information and materials relevant to my medical specialization and, to the extent possible, my professional interests, in the following areas:  

  1. Conceição I, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2016;21:5-9.

  2. Damy T, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transtheyretin amyloidosis. J Cardiovasc Transl Res 2015;8(2):117-27.

  3. Alcantara M, et al. Canadian guidelines for hereditary transthyretin amyloidosis polyneuropathy management. Can J Neurol Sci 2022;49:7-18.

  4. Adams D, et al. Nat Rev Neurol 2019;15:387-404.

  5. Adams D. Ther Adv Neurol Disord 2013;6:129-39.

  6. Hawkins P, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med 2015;47:625-38.

  7. Benson MD, et al. Ther Clin Risk Manag 2020;16:749-58.

  8. Obici L, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 2016;29(suppl 1):S27-S35.

PRIVACY POLICY LEGAL NOTICE CONTACT US
TTR-CAN-00122   Date of preparation: October, 2026.